IP Library Granted Patent US 8,080,414
Granted Patent B2
US 8,080,414 · App. 12/488,465 · Granted Dec 20, 2011

Recombinant cell clones having increased stability and methods of making and using the same

Assignee: Baxter Innovations GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,080,414
App. No.
12/488,465
Granted
Dec 20, 2011
Kind
B2
Abstract

Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.

Claims (22)

1. An isolated recombinant mammalian cell clone stable in serum- and protein-free medium and expressing a recombinant product, wherein said cell clone is stable in serum- and protein-free medium for at least 40 generations with neither selection pressure for a selection marker nor selection for a polypeptide factor that replaces serum components.

2. An isolated recombinant mammalian cell clone as set forth in claim 1 , said cell clone being stable for at least 50 generations.

3. A cell culture comprising at least 90% of stable recombinant mammalian cells expressing a recombinant product, said stable recombinant cells stable for more than 40 generations under serum- and protein-free conditions with neither selection pressure for a selection marker nor selection for a polypeptide factor that replaces serum components.

4. A cell culture as set forth in claim 3 , wherein said stable recombinant cells are stable for more than 50 generations under serum- and protein-free conditions.

5. A cell culture as set forth in claim 3 , wherein said stable recombinant cells contain a sequence encoding for a recombinant polypeptide or recombinant protein.

6. An isolated recombinant CHO cell clone selected with neither selective pressure for a selection marker nor selection for a polypeptide factor that replaces serum components, said cell clone stable in serum- and protein-free medium for at least 40 generations and expressing a recombinant product.

7. An isolated recombinant CHO cell clone as set forth in claim 6 , said cell clone being stable for at least 50 generations.

8. An isolated recombinant CHO cell clone as set forth in claim 6 , wherein said cell clone contains sequences encoding a recombinant polypeptide or said recombinant protein.

9. An isolated recombinant CHO cell clone which has been cultivated in serum- and protein-free medium with neither selective pressure for a selection marker nor selection for a polypeptide factor that replaces serum components for at least 40 generations and which expresses a recombinant product.

10. An isolated recombinant CHO cell clone of claim 9 , wherein the cell clone has been cultivated for at least 50 generations.

11. An isolated recombinant mammalian cell clone of claim 1 , wherein the recombinant cell clone expresses Factor VIII as the recombinant product.

12. An isolated recombinant mammalian cell clone of claim 1 , wherein the recombinant cell clone expresses Factor IX as the recombinant product.

13. An isolated recombinant mammalian cell clone of claim 1 , wherein the recombinant cell clone expresses Factor VII as the recombinant product.

14. An isolated recombinant mammalian cell clone of claim 1 , wherein the recombinant cell clone expresses von Willebrand factor (vWF) as the recombinant product.

15. A cell culture as set forth in claim 3 , wherein said stable recombinant cells express Factor VIII as the recombinant product.

16. A cell culture as set forth in claim 3 , wherein said stable recombinant cells express Factor IX as the recombinant product.

17. A cell culture as set forth in claim 3 , wherein said stable recombinant cells express Factor VII as the recombinant product.

18. A cell culture as set forth in claim 3 , wherein said stable recombinant cells express vWF as the recombinant product.

19. An isolated recombinant CHO cell clone of claim 9 , wherein the cell clone expresses Factor VIII as the recombinant product.

20. An isolated recombinant CHO cell clone of claim 9 , wherein the cell clone expresses Factor IX as the recombinant product.

21. An isolated recombinant CHO cell clone of claim 9 , wherein the cell clone expresses Factor VII as the recombinant product.

22. An isolated recombinant CHO cell clone of claim 9 , wherein the cell clone expresses vWF as the recombinant product.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2015
From: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 036825/0963 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2015
From: BAXTER INNOVATIONS GMBH
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 035424/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2011
From: REITER, MANFRED; MUNDT, WOLFGANG; DORNER, FRIEDRICH
To: BAXTER AKTIENGESELLSCHAFT
Reel/Frame 026902/0994 →
CHANGE OF NAME Recorded Mar 7, 2011
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER INNOVATIONS GMBH
Reel/Frame 025914/0023 →
Priority Claims (1)
AT 1073/97 · Jun 20, 1997 · national
Continuity (6)
Continuation 11482504 · Jul 7, 2006
Division 11123362 · May 6, 2005
Continuation 10170661 · Jun 12, 2002
Continuation 09324612 · Jun 2, 1999
Continuation In Part 09100253 · Jun 19, 1998
Related Publication 20090253178A1 · Oct 8, 2009